Display options
Cite
Ghodsi SM, Mohebbi N, Naderi S, et al. Comparative efficacy of meloxicam and placebo in vasospasm of patients with subarachnoid hemorrhage. Iran J Pharm Res. 2015;14(1):125-30
Ghodsi, S. M., Mohebbi, N., Naderi, S., Anbarloie, M., Aoude, A., & Habibi Pasdar, S. S. (2015). Comparative efficacy of meloxicam and placebo in vasospasm of patients with subarachnoid hemorrhage. Iranian journal of pharmaceutical research : IJPR, 14(1), 125-30.
Ghodsi, Seyed Mohammad, et al. "Comparative efficacy of meloxicam and placebo in vasospasm of patients with subarachnoid hemorrhage." Iranian journal of pharmaceutical research : IJPR vol. 14,1 (2015): 125-30.
Ghodsi SM, Mohebbi N, Naderi S, Anbarloie M, Aoude A, Habibi Pasdar SS. Comparative efficacy of meloxicam and placebo in vasospasm of patients with subarachnoid hemorrhage. Iran J Pharm Res. 2015;14(1):125-30. PMID: 25561918; PMCID: PMC4277625.
Copy Download .nbib Format: NLM
Share it on

Iran J Pharm Res. 2015;14(1):125-30.

Comparative efficacy of meloxicam and placebo in vasospasm of patients with subarachnoid hemorrhage.

Iranian journal of pharmaceutical research : IJPR

Seyed Mohammad Ghodsi, Niayesh Mohebbi, Soheil Naderi, Mousareza Anbarloie, Ahmad Aoude, Seyed Sohail Habibi Pasdar

Affiliations

  1. Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran.
  2. Department of Clinical Pharmacy, Faculty of Pharmacy and Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.
  3. Department of Internal Medicine, University of Arizona, Arizona, United States of America.

PMID: 25561918 PMCID: PMC4277625

Abstract

Cerebral vasospasm considered to be a serious cause of morbidity and mortality following subarachnoid haemorrhage (SAH).Despite several available therapeutic options, current protocols do not prevent major consequences of vasospasm. Inflammation is believed to play an important role in post-haemorrhagic vasospasm. Meloxicam is a non-steroidal anti-inflammatory drug. The aim of this study was to compare the efficacy of meloxicam versus placebo on vasospasm in patients with SAH. In this randomized, double-blind, placebo-controlled trial, SAH patients randomly received 7.5 mg meloxicam or placebo twice daily for 7 days. End points were, middle cerebral artery velocity obtained with transcranial doppler, in-hospital mortality, hospital stay and discharge Glasgow Outcome Scale. Eighty-one patients enrolled in the study. (40 received meloxicam, 41 received placebo). Baseline characteristics were similar between the groups. There were no differences in length of hospitalization (17.4 ± 3.1 vs 18.6 ± 4.2 days; p = 0.145), in-hospital mortality rate (15 vs 22%; p-value=0.569), or GOS (p = 0.972) between the two groups. MCA velocity were slightly less in patients who had received meloxicam, but not to a significant degree (p-value=0. 564(. No side effect has been detected for meloxicam. This study did not prove meloxicam efficacy in vasospasm of SAH patients. But it demonstrated that clinical trial of meloxicam in these patients is feasible and probably safe. The effectiveness of meloxicam on cerebral vasospasm has to be studied in larger trials.

Keywords: Anti-inflammatory drugs; Cerebral vasospasm; Meloxicam; Subarachnoid haemorrhage

References

  1. Neurosurgery. 1983 Jan;12(1):40-6 - PubMed
  2. Inflamm Res. 1998 Jul;47(7):302-7 - PubMed
  3. Acta Neurochir (Wien). 2010 May;152(5):855-60 - PubMed
  4. Neurol Res. 2002 Mar;24(2):215-22 - PubMed
  5. Pharmacology. 1997 Jul;55(1):44-53 - PubMed
  6. J Clin Neurosci. 2008 Jan;15(1):55-9 - PubMed
  7. Neurosurgery. 2003 Jul;53(1):123-33; discussion 133-5 - PubMed
  8. Drug Discov Today. 2008 Mar;13(5-6):254-60 - PubMed
  9. Stroke. 2001 Sep;32(9):2012-20 - PubMed
  10. Neurology. 2000 Feb 22;54(4):872-8 - PubMed
  11. J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):534-7 - PubMed
  12. Iran J Pharm Res. 2013 Spring;12(2):461-8 - PubMed
  13. Acta Neurochir Suppl. 2008;105:225-8 - PubMed
  14. Neurosurgery. 1998 Oct;43(4):863-75; discussion 875-6 - PubMed
  15. Stroke. 1999 Jan;30(1):140-7 - PubMed
  16. Iran J Pharm Res. 2013 Spring;12(2):389-94 - PubMed
  17. Neurosurgery. 2003 May;52(5):1188-94; 1194-5 - PubMed
  18. Stroke. 2002 Jan;33(1):200-8 - PubMed
  19. Stroke. 2001 Jan;32(1):212-7 - PubMed
  20. J Neurosurg. 2004 Jul;101(1):93-8 - PubMed
  21. Stroke. 1989 Aug;20(8):1021-6 - PubMed
  22. Biochem Pharmacol. 1996 Jan 12;51(1):29-38 - PubMed
  23. Acta Neurochir (Wien). 2009 Sep;151(9):1135-41 - PubMed
  24. Neurosurg Focus. 2006 Sep 15;21(3):E9 - PubMed
  25. J Neurosurg. 1995 Jun;82(6):945-52 - PubMed
  26. Brain. 2001 Feb;124(Pt 2):249-78 - PubMed
  27. Acta Neurochir (Wien). 2007 Oct;149(10):1041-7; discussion 1047-8 - PubMed
  28. Stroke. 1997 Mar;28(3):660-4 - PubMed
  29. Neurol Med Chir (Tokyo). 1991 Jan;31(1):24-31 - PubMed
  30. Neurosurgery. 1987 Aug;21(2):157-60 - PubMed
  31. Neurosurg Clin N Am. 1998 Jul;9(3):615-27 - PubMed

Publication Types